8-K: Collegium Raises 2025 Outlook on Record Q2 Revenue

Collegium Pharmaceutical reported strong second quarter 2025 financial results, driven by record net revenue and growth in its ADHD and pain portfolios, leading to an increased full-year 2025 financial outlook.

Summary

• Generated record quarterly net revenue of $188.0 million in Q2 2025, a 29% increase year-over-year compared to $145.3 million in Q2 2024.
• Jornay PM net revenue reached a record $32.6 million in Q2 2025, with prescriptions growing 23% year-over-year and prescribers reaching an all-time high of over 26,000.
• The pain portfolio generated $155.4 million in net revenue in Q2 2025, up 7% year-over-year, with all three core products (Belbuca, Xtampza ER, Nucynta Franchise) recording revenue growth.
• Raised full-year 2025 net revenue guidance to a range of $745 million to $760 million, up from the prior range of $735 million to $750 million.
• Increased full-year 2025 Adjusted EBITDA guidance to a range of $440 million to $455 million, up from the prior range of $435 million to $450 million.
• Ended Q2 2025 with cash, cash equivalents, and marketable securities of $222.2 million, and generated $72.4 million in cash from operations.
• The Board of Directors authorized a new $150 million share repurchase program through December 31, 2026, following the completion of a $25 million accelerated share repurchase program in July 2025.

Sentiment

Score: 8

Explanation: The filing presents a strong positive outlook, driven by record revenue, significant growth in key products (Jornay PM), and increased full-year financial guidance. The commitment to shareholder value through substantial share repurchase programs further enhances positive sentiment. While GAAP net income declined, the focus on adjusted metrics and strategic investments for future growth mitigate this concern, indicating a robust operational performance and strategic direction.

Positives

• Record quarterly net revenue of $188.0 million, representing a 29% year-over-year increase.
• Strong growth in Jornay PM, with 23% year-over-year prescription growth and record net revenue of $32.6 million.
• Pain portfolio net revenue grew 7% year-over-year to $155.4 million, with all core products showing growth.
• Raised full-year 2025 net revenue guidance to $745-$760 million, indicating strong anticipated performance.
• Increased full-year 2025 Adjusted EBITDA guidance to $440-$455 million, reflecting improved profitability outlook.
• Generated $72.4 million in cash from operations in Q2 2025, demonstrating robust cash flow.
• Ended Q2 2025 with a healthy cash position of $222.2 million in cash, cash equivalents, and marketable securities.
• Authorization of a new $150 million share repurchase program signals commitment to shareholder value.
• Completed a $25 million accelerated share repurchase program, returning value to shareholders.

Negatives

• GAAP net income for Q2 2025 decreased to $12.0 million from $19.6 million in Q2 2024, a 39% year-over-year decline.
• GAAP operating expenses increased significantly by 69% year-over-year to $73.3 million in Q2 2025.
• Adjusted operating expenses increased by 104% year-over-year to $61.9 million in Q2 2025, primarily due to investments in the Jornay PM sales force.

Risks

• Unknown liabilities could impact financial performance.
• Uncertainty regarding the expected financial performance of products.
• Challenges in commercializing and growing sales of products.
• Ability to manage relationships with licensors may affect operations.
• Success of competing products could impact market share and revenue.
• Maintaining regulatory approval for products and managing related restrictions/warnings.
• Ability to accurately assess and service the size of product markets.
• Obtaining reimbursement and third-party payor contracts for products.
• Rate and degree of market acceptance of products may vary.
• Costs associated with commercialization activities, including marketing, sales, and distribution.
• Changing market conditions for products could affect demand and pricing.
• Potential outcomes of patent infringement or other litigation.
• Outcomes of governmental investigations related to the business.
• Ability to secure adequate supplies of active pharmaceutical ingredients and manufacture sufficient inventory.
• Ability to obtain funding for operations and business development initiatives.
• Impact of regulatory developments in the U.S. on business operations.
• Ability to obtain and maintain sufficient intellectual property protection for products.
• Compliance with stringent U.S. and foreign government regulations in pharmaceutical manufacturing, including DEA compliance.
• Customer concentration could pose risks to revenue stability.
• Accuracy of estimates regarding expenses, revenue, capital requirements, and need for additional financing.

Future Outlook

The company anticipates a strong back-to-school season and second half of the year for Jornay PM, leading to increased full-year 2025 net revenue guidance of $745 million to $760 million and Adjusted EBITDA guidance of $440 million to $455 million. Management expects to continue driving topand bottom-line growth, evaluating external opportunities for portfolio expansion through business development, and generating shareholder value through disciplined capital deployment, including further debt reduction to achieve a net leverage of less than 1.0x by year-end 2025.

Management Comments

• "We continued to generate strong momentum in the second quarter, driven by sustained execution across our three strategic priorities, including record revenue from Jornay PM, maximizing our pain portfolio, and strategically deploying capital to enhance shareholder value." Vikram Karnani, President and Chief Executive Officer.
• "Following encouraging performance in the first half of the year, we anticipate a strong back-to-school season and second half of the year for Jornay PM and have raised our full-year revenue guidance accordingly." Vikram Karnani, President and Chief Executive Officer.
• "Additionally, our pain portfolio generated solid revenue growth in the quarter, reinforcing the durability of our differentiated medicines to treat chronic pain." Vikram Karnani, President and Chief Executive Officer.
• "We delivered another impressive quarter characterized by record quarterly revenue, robust adjusted EBITDA, and significant cash flow generation, leading us to increase our 2025 financial guidance." Colleen Tupper, Chief Financial Officer.
• "We now expect to grow full-year revenue by 19%, with Jornay PM net revenue expected between $140 to 145 million, and adjusted EBITDA to grow by 12%, compared to 2024." Colleen Tupper, Chief Financial Officer.
• "We will continue to evaluate external opportunities to expand our portfolio through business development and generate shareholder value through our capital deployment strategies, as demonstrated by the recent completion of a $25 million accelerated share repurchase program and the announcement of a new $150 million share repurchase program authorized through the end of 2026." Colleen Tupper, Chief Financial Officer.

Industry Context

Collegium Pharmaceutical operates in the biopharmaceutical sector, specifically focusing on pain management and neuropsychiatry (ADHD). The strong growth in Jornay PM prescriptions and revenue indicates a successful penetration into the ADHD market, which is a competitive but growing segment. The continued growth in the pain portfolio, despite ongoing scrutiny in the opioid market, highlights the durability and differentiation of its responsible pain management medications. The company's strategy of disciplined capital deployment, including share repurchases and potential business development, aligns with broader industry trends of companies seeking to enhance shareholder value and diversify product portfolios.

Comparison to Industry Standards

• The filing does not provide specific comparable companies, projects, or results for direct industry standard comparisons. However, the company highlights Jornay PM as the 'Fastest Growing Stimulant for Treatment of ADHD' and 'highest rated branded ADHD medicine in terms of product differentiation' based on market research, suggesting strong competitive positioning within its therapeutic area.
• Belbuca is noted as the '#1 highest rated branded ER opioid in terms of product differentiation and favorability', and Xtampza ER as the '#1 highest rated ER oxycodone in terms of product differentiation and favorability', indicating strong product perception within the pain management segment.

Management Changes

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to increased financial guidance, strong revenue growth, robust cash generation, and significant share repurchase programs aimed at enhancing shareholder value.
• Patients: Positive impact as the company continues to focus on improving the lives of people with serious medical conditions through its growing portfolio of differentiated medicines for ADHD and chronic pain.
• Employees: Potential positive impact for the sales force with the expansion of the ADHD sales team to approximately 180 representatives, indicating growth opportunities.
• Creditors: Positive impact due to the company's focus on rapidly paying down debt and expecting to achieve a net leverage of less than 1.0x by year-end 2025, improving financial stability.

Next Steps

• Participate in the Piper Sandler CNS Symposium (Virtual) on August 14, 2025.
• Participate in the 2025 Wells Fargo Healthcare Conference in Boston, MA on September 4, 2025.
• Participate in the Morgan Stanley 23rd Annual Global Healthcare Conference in New York, NY on September 8, 2025.
• Participate in the H.C. Wainwright 26th Annual Global Investment Conference in New York, NY on September 9, 2025.
• Continue to invest in Jornay PM to support near-term growth and create momentum in 2026 and beyond.
• Increase adoption of Jornay PM in an expanded set of prescribers and raise awareness in patients and caregivers.
• Maximize and enhance the durability of the pain portfolio to generate durable operating cash flows.
• Expand the portfolio through disciplined business development.
• Rapidly pay down debt and opportunistically repurchase shares, aiming for net leverage of less than 1.0x by year-end 2025.

Key Dates

Recommendation

The filing indicates strong operational performance with record quarterly revenue and significant growth in key product lines, particularly Jornay PM. The company has raised its full-year revenue and Adjusted EBITDA guidance, signaling confidence in continued growth. Furthermore, the authorization of a new $150 million share repurchase program underscores a commitment to returning capital to shareholders and suggests management believes the stock is undervalued. While GAAP net income saw a decline, the robust non-GAAP metrics and strategic investments for future growth outweigh this, making Collegium an attractive investment.

Keywords

Pharmaceutical, ADHD, Pain Management, Jornay PM, Belbuca, Xtampza ER, Nucynta, Financial Results, Earnings, Guidance, Share Repurchase, Biopharmaceutical, SEC Filing